EXEL - Exelixis reports positive results for Cabometyx in pancreatic cancer
2023-08-24 08:47:07 ET
More on Exelixis
- Exelixis: Stock Likely To Break Out Of 5-Year Inertia
- Exelixis: Thriving Investment Opportunity In The Evolving World Of Oncology
- Exelixis lead product hits main goal in Phase 3 prostate cancer trial
- Exelixis a new overweight at Piper Sandler on Cabometyx, pipeline
- Seeking Alpha’s Quant Rating on Exelixis
For further details see:
Exelixis reports positive results for Cabometyx in pancreatic cancer